Edition:
India

Akebia Therapeutics Inc (AKBA.OQ)

AKBA.OQ on NASDAQ Stock Exchange Global Market

15.44USD
13 Dec 2017
Change (% chg)

$0.13 (+0.85%)
Prev Close
$15.31
Open
$15.30
Day's High
$15.67
Day's Low
$15.27
Volume
37,295
Avg. Vol
152,860
52-wk High
$20.25
52-wk Low
$7.78

Latest Key Developments (Source: Significant Developments)

Akebia Therapeutics reports Q3 loss per share $0.49
Thursday, 9 Nov 2017 

Nov 8 (Reuters) - Akebia Therapeutics Inc :Akebia Therapeutics announces third quarter 2017 financial results.Q3 loss per share $0.49.Q3 earnings per share view $-0.51 -- Thomson Reuters I/B/E/S.Akebia Therapeutics Inc -cash, cash equivalents and available for sale securities $329.7 million at sept 30 versus $260.3 million as at dec 31, 2016​.  Full Article

Akebia Therapeutics provides update on Janssen deal
Monday, 13 Feb 2017 

Akebia Therapeutics Inc : Akebia Therapeutics - Janssen could be eligible to receive up to aggregate of $16.5 million from co in specified development milestone payments . Akebia Therapeutics - Janssen to be eligible to receive up to $215 million from co in specified commercial milestones as well as tiered, escalating royalties . Akebia Therapeutics - unless earlier terminated, deal will expire on a product-by-product and country-by-country basis upon expiration of last royalty term .Akebia Therapeutics-co may terminate deal in its entirety or only with respect to particular licensed compound upon 180 days' prior written notice to Janssen.  Full Article

Akebia to pay Janssen to access come intellectual property
Monday, 13 Feb 2017 

Akebia Therapeutics Inc - : Will pay Janssen $1.0 million in cash to access their collection of hundreds of HIF-targeted compounds, associated intellectual property . Co obtains worldwide rights to akb-5169, a non-absorbed oral HIF stabilizer in preclinical development for treatment of IBD . Johnson & Johnson innovation has opportunity to take ownership interest in co through common stock purchase warrant issued by co to JJDC . JJDC can take ownership interest in co through common stock purchase warrant issued by co to JJDC for 509,611 shares of co's common stock .Warrant exercisable by JJDC, in whole or in part, at any time prior to 5th anniversary of date of issuance with payment to co of up to $5 million.  Full Article

Akebia Therapeutics Q2 earnings per share view $-0.57 -- Thomson Reuters I/B/E/S
Tuesday, 9 Aug 2016 

Akebia Therapeutics Inc : Akebia announces second quarter 2016 financial results . Q2 loss per share $0.95 .Q2 earnings per share view $-0.57 -- Thomson Reuters I/B/E/S.  Full Article

Akebia Therapeutics Announces Proposed Public Offering of Common Stock
Tuesday, 5 Jan 2016 

Akebia Therapeutics Inc :Announces proposed public offering of common stock.Says intends to offer and sell $75 million of shares of its common stock in an underwritten public offering.To use proceeds for the continued clinical development of vadadustat in patients with anemia secondary to ckd.Net proceeds are also intended to be used to advance its product candidate, akb-6899, through phase 1 development in oncology.  Full Article

BRIEF-Akebia Therapeutics reports Q3 loss per share $0.49

* Akebia Therapeutics announces third quarter 2017 financial results